Teladoc Health (NYSE:TDOC) Stock Sees Unusually High Call Option Buying

Key Points

• Unusual bullish options activity drove attention to Teladoc, with call-option volume reaching 15,699 contracts—132% above its typical daily level. The stock surged 26.8% to $8.72 on volume nearly four times its average.
• Teladoc’s latest quarter beat expectations, reporting $605.1 million in revenue and a $0.15-per-share loss versus forecasts for $588.1 million and a $0.22 loss. The company also improved its profitability outlook and cited progress in BetterHelp’s insurance transition.
• Despite the rally, analysts remain cautious: the consensus rating is “Hold” with an average price target of $7.57, below the current price. Revenue continues to decline year over year, losses persist, and near-term guidance remains mixed.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders bought 15,699 call options on the company. This represents an increase of 132% compared to the typical daily volume of 6,766 call options.

Teladoc Health Stock Up 26.8%

TDOC stock traded up $1.84 during mid-day trading on Thursday, reaching $8.72. 20,077,667 shares of the stock traded hands, compared to its average volume of 5,096,983. The business has a 50-day moving average of $6.15 and a two-hundred day moving average of $6.46. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.89. The firm has a market capitalization of $1.58 billion, a PE ratio of -8.81 and a beta of 2.14.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The business had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm's revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.28) earnings per share. On average, equities research analysts anticipate that Teladoc Health will post -0.92 EPS for the current fiscal year.

Key Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results exceeded expectations. Revenue was $605.1 million, down approximately 3% year over year but above the roughly $588 million consensus estimate. The company reported a net loss of $0.15 per share, narrower than expected and improved from the prior-year loss. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Profitability guidance improved. Teladoc raised its full-year 2026 GAAP earnings-per-share outlook and reported stronger adjusted EBITDA, supporting the view that cost controls and operating improvements are beginning to offset stagnant or declining revenue. Teladoc Stock Rallies After Double Beat
• Positive Sentiment: BetterHelp’s insurance transition offered an additional catalyst. Insurance-related BetterHelp revenue reached $32 million in Q3, and management is targeting an insurance-exit run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, which could reduce debt and potentially improve per-share value. Teladoc Targets BetterHelp Insurance Exit Run Rate
• Positive Sentiment: Trading activity showed strong speculative interest. Call-option volume was more than double its average, while the stock moved above its 200-day moving average, potentially attracting momentum-oriented buyers.
• Neutral Sentiment: Near-term guidance was mixed. Teladoc forecast fourth-quarter revenue in a range of $569 million to $615 million, reflecting continued uncertainty about demand and growth.
• Negative Sentiment: Analysts remain cautious. Stifel raised its price target to $6.50 but maintained a “hold” rating, while Needham reaffirmed its hold rating. Those targets remain below the current trading level, highlighting concerns about continued revenue declines and ongoing losses. Stifel Nicolaus rating

Insider Buying and Selling

In other Teladoc Health news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the transaction, the chief executive officer owned 465,535 shares of the company's stock, valued at $2,839,763.50. The trade was a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in Teladoc Health by 1.3% in the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider's stock valued at $44,066,000 after buying an additional 107,400 shares in the last quarter. Pale Fire Capital SE lifted its stake in Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock valued at $18,522,000 after acquiring an additional 1,454,288 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Teladoc Health in the second quarter valued at approximately $26,864,000. Quantinno Capital Management LP increased its stake in Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock valued at $14,287,000 after buying an additional 1,471,631 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC grew its holdings in shares of Teladoc Health by 1,017.4% in the 3rd quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider's stock valued at $9,571,000 after acquiring an additional 1,502,488 shares in the last quarter. Institutional investors own 76.82% of the company's stock.

Wall Street Analysts Forecast Growth

TDOC has been the subject of several research analyst reports. Bank of America upped their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a "buy" rating in a report on Tuesday, July 7th. Canaccord Genuity Group cut their price objective on Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Needham & Company LLC restated a "hold" rating on shares of Teladoc Health in a research report on Thursday. Citigroup decreased their price objective on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a research report on Monday, August 3rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a report on Wednesday, August 19th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $7.57.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.